Eli Lilly and CoNYSE:LLY

Help
Symbol Lookup
    No Matches were found for
    Additional matches for ...
     
    Go
    OverviewChartsNewsFundamentalsEarningsReportsCalendarOptionsTechnical Insight

    Symbol Lookup

    Close

    Search Criteria

    Name or Symbol

    Security Type

    Fund Categories

    Market

    Expiration Filter

    Chain Type

    Submit
    Wednesday June 19, 2013 7:38 AM ET. Data delayed 15 minutes.
    52.35
    0.00 (0.00%)
    Price HistoryRefresh
    Bid/Lots
    49.62/1
    Ask/Lots
    52.97/6
    Open/Prev Close
    0.00/52.35
    Day Range
    -----
    52-Week Range
    41.41-58.41
    Vol/Avg Daily Vol
    0.0/5.0M

    LLY Article

    Go

    Today

    Market Chatter: Eli Lilly's Zyprexa Subject of FDA Investigation
    20 minutes ago by Midnight Trader
    Companies Mentioned: LLY
    07:17 AM EDT, 06/19/2013 (MidnightTrader) -- Eli Lilly's (LLY) drug Zyprexa is being investigated by the FDA after two patients died after taking it, Bloomberg reports. Zyprexa is an antipsychotic. Eli Lilly shares are flat in pre-market at $52.3...
    UPDATE 1-AstraZeneca, Bristol diabetes drug disappoints in key test
    4 hours ago by Thomson Reuters
    Companies Mentioned: LLY, BMY

    * Onglyza fails to show cardiovascular benefit in study

    * Positive results might have added $1 bln to peak sales

    * Drug achieves non-inferiority goal ve...

    Yesterday

    Ely Lilly to Pay $0.49 Dividend, Same Payout Since Nov. 2009; Stock Off 1%
    20 hours ago by Midnight Trader
    Companies Mentioned: LLY
    10:55 AM EDT, 06/18/2013 (MidnightTrader) -- Eli Lilly (LLY) said it will pay a dividend for the third quarter of 2013 of $0.49 per share on outstanding common stock, maintaining the same payout rate since Nov. 2009, according to Nasdaq data. The...
    Lilly Declares Third-Quarter 2013 Dividend
    21 hours ago by PR Newswire
    Companies Mentioned: LLY

    The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2013 of $0.49 per share on outstanding common stock.

    The dividend is payable September 10, 2013 to shareholders of record at the...

    Jun 17, 2013

    New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia
    11:30AM ET on Monday Jun 17, 2013 by PR Newswire
    Companies Mentioned: LLY

    Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evalu...

    Lilly Diabetes, Kris Freeman Kick off Summer with 9th Annual Diabetes Summer Camp Tour
    8:00AM ET on Monday Jun 17, 2013 by PR Newswire
    Companies Mentioned: LLY

    News Highlights

    -- #T1DiabetesChamp Kris Freeman @TeamFreeBirdXC visits 10 #diabetes #camps; has helped inspire more than 6,500 campers through Lilly program

    -- Lilly is one of the largest supporters of #diabetes #camps in the US ...

    Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly; Shares Rose 3% To Near Yr Highs Friday
    7:55AM ET on Monday Jun 17, 2013 by Midnight Trader
    Companies Mentioned: LLY, TTHI
    07:55 AM EDT, 06/17/2013 (MidnightTrader) -- Transition Therapeutics Inc. (TTHI, TTH.TO), which rose more than 3% Friday to near a year high $3.85 on the TSX, announced that Eli Lilly and Company (LLY) has exercised its option to assume all devel...
    Eli Lilly Exercises Option with Transition Therapeutics on Diabetes Drug TT-401
    7:12AM ET on Monday Jun 17, 2013 by Midnight Trader
    Companies Mentioned: LLY, TTHI
    07:12 AM EDT, 06/17/2013 (MidnightTrader) -- Transition Therapeutics Inc. (TTHI) announced that Eli Lilly and Company (LLY) has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. ...
    Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly
    6:01AM ET on Monday Jun 17, 2013 by CNW Group
    Companies Mentioned: LLY, TTH, TTHI

    Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Eli Lilly and Company ("Lilly") has exercised its option to assume all development and commercialization rights to type 2 diabetes drug cand...

    Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly
    6:01AM ET on Monday Jun 17, 2013 by PR Newswire
    Companies Mentioned: LLY, TTH, TTHI

    Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Eli Lilly and Company ("Lilly") has exercised its option to assume all development and commercialization rights to type 2 diabetes drug cand...

    ← Newer12345Older →

    K=Thousands, M=Millions, B=Billions, TTM=Trailing 12 Month, MRQ=Most Recent Quarter, FYR=Fiscal Year End, NM=Not Meaningful, NA=Not Available

    GAAP = Generally Accepted Accounting Principles used in Financial Statements issued by the company, Non-GAAP = Adjusted Operating Earnings or Revenue used in comparison to Analyst Estimates. Adjustments are typically one-time gains or losses

    7:38 AM June 19, 2013
    Copyright ©2013 TD Waterhouse Canada Inc. All rights reserved.
    Privacy Policy | Internet Security | Legal
    Quotes, News, and Fundamentals provided by
    View restrictions
    News provided by